SWOG clinical trial number
SWOG-9343

Evaluation of Combined Androgen Suppression and Fixed Schedule Suramin in Patients with Newly Diagnosed Metastatic Prostate Cancer, Phase II

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Advanced Prostate
Activated
08/15/1994
Closed
01/15/1997

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2000

Androgen deprivation and four courses fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: a Southwest Oncology Group study

MHA Hussain;EI Fisher;DP Petrylak;J O'Connor;DP Wood;EJ Small;MA Eisenberger;ED Crawford Journal of Clinical Oncology 18(5):1043-1049

1998

Androgen deprivation (AD) + 4-courses of fixed-schedule suramin in D2 prostate cancer (PCA) patients (pts): A Southwest Oncology Group phase II study.

M Hussain;E Fisher;D Wood;E Small;M Eisenberger;ED Crawford Proc of the American Society of Clinical Oncology 17:314a(#1211)

Analysis of suramin (S) levels obtained from D2 hormone naive prostate cancer (HNPCA) patients (pts) treated with fixed bolus suramin: A Southwest Oncology Group study.

DP Petrylak;JO Connor;E Fisher;M Eisenberger;ED Crawford;M Hussain Proc of the American Society of Clinical Oncology 17:340a(#1310)

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase